연구동향 분석

Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases

Han Ah Lee Young Chang Pil Soo Sung Eileen L. Yoon Hye Won Lee Jeong-Ju Yoo Young-Sun Lee Jihyun An Do Seon Song Young Youn Cho Seung Up Kim Yoon Jun Kim 2022년

논문상세정보
인용/피인용
' Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • Non-antidiabetic drugs
  • Treatment
  • cirrhosis
  • non-alcoholic fatty liver disease
  • viralhepatitis
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
644 0

0.0%

' Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases' 의 참고문헌

  • 알라닌아미노전달효소가 상승된 만성간질환 환자에서 Biphenyl Dimethyl Dicarboxylate와 Ursodeoxycholic Acid의 유효성과 안정성을 평가하는 무작위배정, 이중맹검, 다기관 제4상 임상시험
    이세환 [2014]
  • 만성 간질환에서 펜넬Ⓡ의 무작위, 이중맹검, 다기관 제4상임상시험
    김형준 [2014]
  • miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease
    Castro RE [2013]
  • linking action mechanisms to therapeutic applications
    Roma MG [2011]
  • ffects of vitamin E on chronic hepatitis C genotype 3: a randomized, double-blind, placebo-controlled study
  • Vitamin E improves the aminotransferase status of patients suffering from viral hepatitis C : a randomized, double-blind, placebo-controlled study
  • Vitamin E as treatment for chronic hepatitis B : results of a randomized controlled pilot trial
    Andreone P [2001]
  • Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis
    Harrison SA [2003]
  • Vitamin E and the risk of prostate cancer : the Selenium and Vitamin E Cancer Prevention Trial(SELECT)
    Klein EA [2011]
  • Vitamin E : an overview of major research directions
    Zingg JM [2007]
  • Use of statins in patients with chronic liver disease and cirrhosis : current views and prospects
    Vargas JI [2017]
  • Ursodeoxycholic acid therapy in cystic fibrosisassociated liver disease : a dose-response study
    Colombo C [1992]
  • Ursodeoxycholic acid stimulates the formation of the bile canalicular network
    Ikebuchi Y [2012]
  • Ursodeoxycholic acid stimulates Nrf2-mediated hepatocellular transport, detoxification, and antioxidative stress systems in mice
    Okada K [2008]
  • Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis : a pilot study
    Laurin J [1996]
  • Ursodeoxycholic acid in primary biliary cirrhosis : results of a controlled double-blind trial
    Leuschner U [1989]
  • Ursodeoxycholic acid impairs liver-infiltrating T-cell chemotaxis through IFN-γ and CX3CL1 production in primary biliary cholangitis
    Shimoyama S [2021]
  • Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis : results of a randomized trial
    Lindor KD [2004]
  • Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity
    Mueller M [2015]
  • Ursodeoxycholic acid decreases age-related adiposity and inflammation in mice
    오아름 [2016]
  • Ursodeoxycholic acid attenuates experimental autoimmune arthritis by targeting Th17 and inducing pAMPK and transcriptional corepressor SMILE
    Lee EJ [2017]
  • Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases : an overview of their mechanisms of action
    Poupon R [2012]
  • Ursodeoxycholic acid alleviates nonalcoholic fatty liver disease by inhibiting apoptosis and improving autophagy via activating AMPK
    Wu P [2020]
  • Ursodeoxycholic acid : effects on hepatic unfolded protein response, apoptosis and oxidative stress in morbidly obese patients
    Mueller M [2018]
  • Urea cycle dysregulation in non-alcoholic fatty liver disease
    De Chiara F [2018]
  • Treatment options for nonalcoholic fatty liver disease : a double-blinded randomized placebo-controlled trial
  • Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study
    Wong VW [2013]
  • Treatment efficacy of a probiotic preparation for nonalcoholic steatohepatitis : a pilot trial
    Manzhalii E [2017]
  • Tocotrienols for normalisation of hepatic echogenic response in nonalcoholic fatty liver : a randomised placebocontrolled clinical trial
    Magosso E [2013]
  • Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis : a randomized controlled trial
  • Therapeutic mechanisms of bile acids and nor-ursodeoxycholic acid in non-alcoholic fatty liver disease
  • The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins
    Marrone G [2013]
  • The role of branched chain amino acids in the treatment of hepatic encephalopathy
    Dam G [2018]
  • The effect of synbiotic supplementation on body composition and lipid profile in patients with nafld : a randomized, double blind, placebo-controlled clinical trial study
    Asgharian A [2017]
  • The effect of antioxidant supplementation on hepatitis C viral load, transaminases and oxidative status : a randomized trial among chronic hepatitis C virus-infected patients
    Groenbaek K [2006]
  • The diagnosis and management of nonalcoholic fatty liver disease : Practice guidance from the American association for the study of liver diseases
  • The Effect of Dimethyl Dimethoxy Biphenyl Dicarboxylate (DDB) againstTamoxifen-induced Liver Injury in Rats: DDB Use Is Curative or Protective
  • The Asia-Pacific working party on non-alcoholic fatty liver disease guidelines 2017-part 2 : management and special groups
    Chitturi S [2018]
  • Targeting dysbiosis for the treatment of liver disease
    Anand G [2016]
  • Systematic review with network meta-analysis : comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH
    Majzoub AM [2021]
  • Systematic review with meta-analysis : the effects of probiotics in nonalcoholic fatty liver disease
    Xiao MW [2019]
  • Systematic review with meta-analysis : the effects of non-steroidal antiinflammatory drugs and anti-platelet therapy on the incidence and recurrence of hepatocellular carcinoma
    Tan RZH [2021]
  • Systematic review with meta-analysis : the effect of vitamin E supplementation in adult patients with non-alcoholic fatty liver disease
    Vadarlis A [2021]
  • Synbiotics alter fecal microbiomes, but not liver fat or fibrosis, in a randomized trial of patients with nonalcoholic fatty liver disease
    Scorletti E [2020]
  • Synbiotic supplementation in nonalcoholic fatty liver disease : a randomized, double-blind, placebocontrolled pilot study
  • Synbiotic supplementation in lean patients with nonalcoholic fatty liver disease : a pilot, randomised, double-blind, placebo-controlled, clinical trial
    Mofidi F [2017]
  • Supplementation of branched-chain amino acids decreases fat accumulation in the liver through intestinal microbiotamediated production of acetic acid
    Iwao M [2020]
  • Statins:pros and cons
  • Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease
  • Statins reduce the risk of cirrhosis and its decompensation in chronic hepatitis B patients : a nationwide cohort study
    Huang YW [2016]
  • Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes : a histopathological followup study
    Ekstedt M [2007]
  • Statins for prevention of cardiovascular disease in adults : evidence report and systematic review for the US preventive services task force
    Chou R [2016]
  • Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis C-related compensated cirrhosis
    Mohanty A [2016]
  • Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C
    Simon TG [2015]
  • Statin use in patients with cirrhosis : a retrospective cohort study
    Kumar S [2014]
  • Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection
    Yang YH [2015]
  • Statin use and non-alcoholic steatohepatitis in at risk individuals
  • Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population : a propensity score landmark analysis
    Hsiang JC [2015]
  • Statin Use and Reduced Hepatocellular Carcinoma Risk in Patients With Nonalcoholic Fatty Liver Disease
    Biyao Zou [2022]
  • Spirulina platensis versus silymarin in the treatment of chronic hepatitis C virus infection. A pilot randomized, comparative clinical trial
    Yakoot M [2012]
  • Simvastatin modulates the adhesion and growth of hepatocellular carcinoma cells via decrease of integrin expression and ROCK
    Relja B [2011]
  • Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension : a randomized controlled trial
    Abraldes JG [2009]
  • Silymarin suppresses hepatic stellate cell activation in a dietary rat model of non-alcoholic steatohepatitis : analysis of isolated hepatic stellate cells
    Kim M [2012]
  • Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons
    Lieber CS [2003]
  • Silymarin protects against acute ethanol-induced hepatotoxicity in mice
    Song Z [2006]
  • Silymarin in treatment of non-alcoholic steatohepatitis : a randomized clinical trial
    Solhi H [2014]
  • Silymarin in non-cirrhotics with non-alcoholic steatohepatitis : a randomized, double-blind, placebo controlled trial
    Navarro VJ [2019]
  • Silymarin as a Natural Antioxidant: An Overview of the Current Evidence and Perspectives
    Peter Surai [2015]
  • Silymarin ameliorates metabolic dysfunction associated with dietinduced obesity via activation of farnesyl X receptor
    Gu M [2016]
  • Silybin-vitamin E-phospholipids complex reduces liver fibrosis in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin
  • Silybin, a component of sylimarin, exerts antiinflammatory and anti-fibrogenic effects on human hepatic stellate cells
  • Silybin dihemisuccinate protects rat erythrocytes against phenylhydrazine-induced lipid peroxidation and hemolysis
  • Silibinin restores NAD+ levels and induces the SIRT1/AMPK pathway in non-alcoholic fatty liver
    Salomone F [2017]
  • Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy
    Ferenci P [2008]
  • Silibinin ameliorates steatosis and insulin resistance during non-alcoholic fatty liver disease development partly through targeting IRS-1/PI3K/Akt pathway
    Zhang Y [2013]
  • Serum oxidative stress markers and lipidomic profile to detect NASH patients responsive to an antioxidant treatment : a pilot study
    Stiuso P [2014]
  • Scavenging of reactive oxygen species and inhibition of arachidonic acid metabolism by silibinin in human cells
    Dehmlow C [1996]
  • Sarcopenia impairs prognosis of patients with liver cirrhosis
    Hanai T [2015]
  • Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes : a randomized controlled trial
    Bril F [2019]
  • Role of ursodeoxycholic acid in prevention of hepatotoxicity caused by amoxicillin-clavulanic acid in rats
  • Role of oxidative stress in pathophysiology of nonalcoholic fatty liver disease
    Masarone M [2018]
  • Response by Ward et al to letter regarding article, "Statin Toxicity : Mechanistic Insights and Clinical Implications"
    Ward NC [2019]
  • Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome
    Kargiotis K [2015]
  • Rationale for the use of statins in liver disease
  • Randomized, double-blind, placebo-controlled study of a multispecies probiotic mixture in nonalcoholic fatty liver disease
    Ahn SB [2019]
  • Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis
    Dufour JF [2006]
  • Randomised double-blinded trial evaluating silymarin for chronic hepatitis C in an Egyptian village : study description and 12-month results
    Tanamly MD [2004]
  • Protective efficacy of vitamins C and E on p, p’-DDT-induced cytotoxicity via the ROS-mediated mitochondrial pathway and NF-κB/FasL pathway
    Jin X [2014]
  • Protective effects of dimethyl-4, 4’-dimethoxy-5, 6, 5’, 6’-dimethylene dioxybiphenyl-2, 2’-dicarboxylate on damages of isolated rat hepatocytes induced by carbon tetrachloride and D-galactosamine
    Fu T [1992]
  • Probiotics prevent hepatic encephalopathy in patients with cirrhosis : a randomized controlled trial
    Lunia MK [2014]
  • Probiotics for the prevention of pediatric antibiotic-associated diarrhea
  • Probiotics for people with hepatic encephalopathy
    Dalal R [2017]
  • Probiotic therapy in patients with nonalcoholic steatohepatitis in Zagazig University Hospitals
  • Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis : a randomized, controlled trial
    Dhiman RK [2014]
  • Primary human hepatocytes are protected against prolonged and repeated exposure to ethanol by silibinin-dihemisuccinate
    van Pelt JF [2003]
  • Primary biliary cholangitis : 2018 practice guidance from the American Association for the Study of Liver Diseases
    Lindor KD [2019]
  • Prevention of free fatty acid-induced hepatic lipotoxicity by carnitine via reversal of mitochondrial dysfunction
    Jun DW [2011]
  • Pravastatin in patients with nonalcoholic steatohepatitis : results of a pilot study
    Rallidis LS [2004]
  • Potential role of branched-chain amino acids in glucose metabolism through the accelerated induction of the glucosesensing apparatus in the liver
    Higuchi N [2011]
  • Platelets mediate cytotoxic T lymphocyteinduced liver damage
    Iannacone M [2005]
  • Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer
    Malehmir M [2019]
  • Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis
    Sanyal AJ [2010]
  • Pharmacological potential of tocotrienols: a review
    Ahsan H [2014]
  • Oxidativeinflammatory damage in cirrhosis : effect of vitamin E and a fermented papaya preparation
    Marotta F [2007]
  • Oxidative stress in chronic hepatitis C : not just a feature of late stage disease
    Jain SK [2002]
  • Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis
    Muto Y [2006]
  • Oral godex capsule for chronic liver disease : a double-blind, randomized, multicenter controlled trial
    Park MS [2001]
  • Oral branched-chain amino acids have a beneficial effect on manifestations of hepatic encephalopathy in a systematic review with meta-analyses of randomized controlled trials
    Gluud LL [2013]
  • On the pharmacology and toxicology of silymarin, an antihepatotoxic active principle from Silybum marianum(L. )Gaertn
    Hahn G [1968]
  • Nutritional supplementation with branched-chain amino acids in advanced cirrhosis : a double-blind, randomized trial
  • Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease : a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial
  • Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis
    Beraza N [2011]
  • Nonalcoholic fatty liver disease : modulating gut microbiota to improve severity?
  • New functions for amino acids : effects on gene transcription and translation
    Kimball SR [2006]
  • Natural history and prognostic indicators of survival in cirrhosis : a systematic review of 118 studies
    D’Amico G [2006]
  • Natural forms of vitamin E : metabolism, antioxidant, and anti-inflammatory activities and their role in disease prevention and therapy
    Jiang Q [2014]
  • NSAID use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: the liver cancer pooling project
    Petrick JL [2015]
  • Mortality in randomized trials of antioxidant supplements for primary and secondary prevention : systematic review and meta-analysis
  • Modulation of nuclear steroid receptors by ursodeoxycholic acid inhibits TGF-beta1-induced E2F-1/p53-mediated apoptosis of rat hepatocytes
    Solá S [2004]
  • Metabolic endotoxemia initiates obesity and insulin resistance
    Cani PD [2007]
  • Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes
    Wolf MJ [2014]
  • Meta-analysis of randomized controlled trials of pharmacologic agents in non-alcoholic steatohepatitis
    Said A [2017]
  • Meta-analysis : high-dosage vitamin E supplementation may increase all-cause mortality
  • Mechanisms of liver injury. III. Oxidative stress in the pathogenesis of hepatitis C virus
    Choi J [2006]
  • Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment
    Ersöz G [2005]
  • Malotilate, a hepatoprotectant, suppresses CYP2E1 expression in rats
    Kim SG [1994]
  • Long-term treatment of latent portosystemic encephalopathy with branched-chain amino acids. A double-blind placebo-controlled crossover study
    Plauth M [1993]
  • Localization of polypyrimidine-tract-binding protein is involved in the regulation of albumin synthesis by branchedchain amino acids in HepG2 cells
    Kuwahata M [2008]
  • Lipopolysaccharide causes an increase in intestinal tight junction permeability in vitro and in vivo by inducing enterocyte membrane expression and localization of TLR-4 and CD14
    Guo S [2013]
  • Lipid-lowering agents that cause drug-induced hepatotoxicity
    Bhardwaj SS [2007]
  • Leucine promotes glucose uptake in skeletal muscles of rats
    Nishitani S [2002]
  • Leaky Gut and Gut-Liver Axis in Liver Cirrhosis: Clinical Studies Update
  • Late evening snack with branched-chain amino acids supplementation improves survival in patients with cirrhosis
    Hanai T [2020]
  • Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis
  • L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy : a double-blind randomized controlled trial
    Jain A [2022]
  • Kinetics, pharmacokinetics, and regulation of Lcarnitine and acetyl-L-carnitine metabolism
    Rebouche CJ [2004]
  • KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
    강성희 [2021]
  • KASL clinical practice guidelines for management of chronic hepatitis B
  • Isoleucine, a potent plasma glucose-lowering amino acid, stimulates glucose uptake in C2C12 myotubes
    Doi M [2003]
  • Intestinal microbiota modulation in obesity-related non-alcoholic fatty liver disease
    Porras D [2018]
  • Interferon/antioxidant combination therapy for chronic hepatitis C--a controlled pilot trial
    Look MP [1999]
  • Interferon and ursodeoxycholic acid combined therapy in chronic viral C hepatitis : controlled randomized trial in 203 patients
    Boucher E [2000]
  • Inhibition of lipopolysaccharide-induced I-kappaB degradation and tumor necrosis factoralpha expression by dimethyl-4, 4’-dimethoxy-5, 6, 5’, 6’-dimethylene dioxybiphenyl-2, 2’-dicarboxylate(DDB) : minor role in hepatic detoxifying enzyme expression
    Kim SG [2000]
  • Inhibition of hepatocarcinogenic responses to 1, 2-dimethylhydrazine by diallyl sulfide, a component of garlic oil
    Hayes MA [1987]
  • Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin
    Dehmlow C [1996]
  • Influence of branched-chain amino acid composition of culture media on the synthesis of plasma proteins by serum-free cultured rat hepatocytes
    Montoya A [1989]
  • In vitro cytotoxic effects of enzymatically induced oxygen radicals in human fibroblasts : experimental procedures and protection by radical scavengers
  • Improvement of regional cerebral blood flow after oral intake of branched-chain amino acids in patients with cirrhosis
    Yamamoto M [2005]
  • Improvement of nonalcoholic fatty liver disease with carnitineorotate complex in type 2 diabetes(CORONA) : a randomized controlled trial
    Bae JC [2015]
  • Impact of silymarin in individuals with nonalcoholic fatty liver disease : a systematic review and metaanalysis
    Kalopitas G [2021]
  • How do statins work? : changing paradigms with implications for statin allocation
    Blaha MJ [2013]
  • High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis : a double-blind, randomized, placebo-controlled trial
  • High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease(NAFLD) : a randomised, double-blind, proof of concept study
    Duseja A [2019]
  • Hepatotoxicity of statins and other lipid-lowering agents
  • Hepatotoxicity associated with statins
    Karahalil B [2017]
  • Hepatoprotection by L-ornithine L-aspartate in non-alcoholic fatty liver disease
  • Hepatitis B, C and D virus infections and risk of hepatocellular carcinoma in Africa : a metaanalysis including sensitivity analyses for studies comparable for confounders
    Mbaga DS [2022]
  • Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis : effect of ursodeoxycholic acid
    Calmus Y [1990]
  • Hepatic effects of lovastatin exposure in patients with liver disease : a retrospective cohort study
    Avins AL [2008]
  • Harms reporting in randomized controlled trials of interventions aimed at modifying microbiota : a systematic review
    Bafeta A [2018]
  • Gut microbiota : its role in hepatic encephalopathy
    Rai R [2015]
  • Gut microbiome and liver diseases
    Tilg H [2016]
  • Gut microbes and hepatic encephalopathy : from the old concepts to new perspectives
    Rocco A [2021]
  • Glucocorticoid receptor-dependent immunomodulatory effect of ursodeoxycholic acid on liver lymphocytes in mice
    Takigawa T [2013]
  • Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017 : a systematic analysis for the Global Burden of Disease Study 2017
  • Global epidemiology of nonalcoholic fatty liver disease-Metaanalytic assessment of prevalence, incidence, and outcomes
    Younossi ZM [2016]
  • Garlic oil and DDB, comprised in a pharmaceutical composition for the treatment of patients with viral hepatitis, prevents acute liver injuries potentiated by glutathione deficiency in rats
    Park EY [2005]
  • Functional modulation of the glucocorticoid receptor and suppression of NF-kappaB-dependent transcription by ursodeoxycholic acid
    Miura T [2001]
  • Extrahepatic platelet-derived growth factor-β, delivered by platelets, promotes activation of hepatic stellate cells and biliary fibrosis in mice
    Yoshida S [2014]
  • Extracellular branched-chain amino acids, especially valine, regulate maturation and function of monocyte-derived dendritic cells
    Kakazu E [2007]
  • Enhanced effectiveness of dimethyl-4, 4’-dimethoxy-5, 6, 5’, 6’-dimethylene dioxybiphenyl-2, 2’-dicarboxylate in combination with garlic oil against experimental hepatic injury in rats and mice
    Kim SG [1995]
  • Efficacy of ursodeoxycholic acid in association with alpha-interferon for chronic hepatitis C in alpha-interferon nonresponder patients
    Fabbri C [2000]
  • Efficacy of statins in treatment and development of nonalcoholic fatty liver disease and steatohepatitis : a systematic review and meta-analysis
    Fatima K [2022]
  • Efficacy of rosuvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia : an open-label, pilot study
    Nakahara T [2012]
  • Efficacy of pitavastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia : an open-label, pilot study
    Hyogo H [2011]
  • Efficacy of lifestyle changes in subjects with non-alcoholic liver steatosis and metabolic syndrome may be improved with an antioxidant nutraceutical : a controlled clinical study
  • Efficacy of l-ornithine l-aspartate for the treatment of hepatic encephalopathy and hyperammonemia in cirrhosis : systematic review and meta-analysis of randomized controlled trials
  • Efficacy of combining pentoxiphylline and vitamin E versus vitamin E alone in non-alcoholic steatohepatitisa randomized pilot study
  • Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia
    Hyogo H [2008]
  • Efficacy of L-ornitin L-aspartate granules in the treatment of chronic liver disease
  • Efficacy and safety of entecavir plus carnitine complex (GODEXⓇ) compared to entecavir monotherapy in patient with ALT elevated chronic hepatitis B: randomized, multicenter open-label trials. The GOAL study
    전대원 [2013]
  • Effects of vitamin E on stroke subtypes : meta-analysis of randomised controlled trials
    Schürks M [2010]
  • Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis
    Balmer ML [2009]
  • Effects of ursodeoxycholic acid and insulin on palmitateinduced ROS production and down-regulation of PI3K/Akt signaling activity
    Yokoyama K [2017]
  • Effects of statin use on the development and progression of nonalcoholic fatty liver disease : a nationwide nested case-control study
    Lee JI [2021]
  • Effects of silybum marianum on patients with chronic hepatitis C
    Kalantari H [2011]
  • Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease
    Nabavi S [2014]
  • Effects of oral branched-chain amino acid granules on eventfree survival in patients with liver cirrhosis
    Muto Y [2005]
  • Effects of metformin, pioglitazone, and silymarin treatment on nonalcoholic fatty liver disease : a randomized controlled pilot study
  • Effects of late evening snack including branched-chain amino acid on the function of hepatic parenchymal cells in patients with liver cirrhosis
    Koreeda C [2011]
  • Effects of in-hospital exercise on liver function, physical ability, and muscle mass during treatment of hepatoma in patients with chronic liver disease
    Koya S [2017]
  • Effects of dietary supplementation with vitamin E and selenium on rat hepatic stellate cell apoptosis
    Shen XH [2005]
  • Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease : a randomized controlled trial
    Polyzos SA [2017]
  • Effects of branched-chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy : a randomized study
    Les I [2011]
  • Effects of branched-chain amino acids on parameters evaluating sarcopenia in liver cirrhosis : systematic review and meta-analysis
    Ismaiel A [2022]
  • Effects of branched-chain amino acids (BCAAs) on the progression of advanced liver disease: a Korean nationwide, multicenter, retrospective, observational, cohort study
    Park JG [2017]
  • Effects of branched-chain amino acid(BCAA)supplementation on the progression of advanced liver disease : a Korean nationwide, multicenter, prospective, observational, cohort study
    Park JG [2020]
  • Effect of vitamins A, E, C and omega-3 fatty acids supplementation on the level of catalase and superoxide dismutase activities in streptozotocin-induced diabetic rats
    Tabei SM [2015]
  • Effect of silymarin(milk thistle)on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy : a randomized controlled trial
    Fried MW [2012]
  • Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study
    Aller R [2015]
  • Effect of side-chain shortening on the physiologic properties of bile acids : hepatic transport and effect on biliary secretion of 23-nor-ursodeoxycholate in rodents
    Yoon YB [1986]
  • Effect of diallyl sulfide on rat liver microsomal nitrosamine metabolism and other monooxygenase activities
    Brady JF [1988]
  • Effect of carnitine-orotate complex on glucose metabolism and fatty liver : a double-blind, placebo-controlled study
    Hong ES [2014]
  • Effect of an oral branched chain amino acid-enriched snack in cirrhotic patients with sleep disturbance
    Ichikawa T [2010]
  • Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons : results from ERCHIVES
    Butt AA [2015]
  • Effect of a probiotic and metformin on liver aminotransferases in non-alcoholic steatohepatitis : a double blind randomized clinical trial
    Shavakhi A [2013]
  • Effect and the probable mechanisms of silibinin in regulating insulin resistance in the liver of rats with non-alcoholic fatty liver
    Yao J [2013]
  • Early administration of branched-chain amino acid granules
    Ishikawa T [2012]
  • EASL-EASD-EASO Clinical practice guidelines for the management of non-alcoholic fatty liver disease
  • EASL clinical practice guidelines : the diagnosis and management of patients with primary biliary cholangitis
  • Do symbiotic and vitamin E supplementation have favorite effects in nonalcoholic fatty liver disease? A randomized, double-blind, placebo-controlled trial
    Ekhlasi G [2016]
  • Differential effect of silybin on the Fe2+-ADP and t-butyl hydroperoxide-induced microsomal lipid peroxidation
  • Diagnosis and management of hepatic encephalopathy
    Rudler M [2021]
  • Delta-tocotrienol supplementation improves biochemical markers of hepatocellular injury and steatosis in patients with nonalcoholic fatty liver disease : A randomized, placebo-controlled trial
    Pervez MA [2020]
  • Daily aspirin use associated with reduced risk for fibrosis progression in patients with nonalcoholic fatty liver disease
    Simon TG [2019]
  • Correction of intrahepatic microcirculation disorders by L-ornithine-L-aspartate at the chronic liver diseases patients
    Ermolova T [2018]
  • Contemporary epidemiology of chronic liver disease and cirrhosis
    Moon AM [2020]
  • Comparison of the effect of BCAA granules on between decompensated and compensated cirrhosis
    Habu D [2009]
  • Comparison of dietary protein with an oral, branched chainenriched amino acid supplement in chronic portal-systemic encephalopathy : a randomized controlled trial
    Horst D [1984]
  • Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease
    Saba Sayari [2018]
  • Clinical course of alcoholic liver cirrhosis : a Danish population-based cohort study
    Jepsen P [2010]
  • Changes in the ratio of branched-chain to aromatic amino acids affect the secretion of albumin in cultured rat hepatocytes
    Okuno M [1995]
  • Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability
    Cani PD [2009]
  • Branched-chain amino acids promote albumin synthesis in rat primary hepatocytes through the mTOR signal transduction system
    Ijichi C [2003]
  • Branched-chain amino acids prevent hepatic fibrosis and development of hepatocellular carcinoma in a non-alcoholic steatohepatitis mouse model
    Takegoshi K [2017]
  • Branched-chain amino acids improve glucose metabolism in rats with liver cirrhosis
    Nishitani S [2005]
  • Branched-chain amino acids for people with hepatic encephalopathy
    Gluud LL [2017]
  • Branched-chain amino acids and muscle ammonia detoxification in cirrhosis
    Dam G [2013]
  • Branched-chain amino acids ameliorate fibrosis and suppress tumor growth in a rat model of hepatocellular carcinoma with liver cirrhosis
    Cha JH [2013]
  • Branched chain amino acids supplementation modulates TGF-β1/Smad signaling pathway and interleukins in CCl4-induced liver fibrosis
    Khedr NF [2017]
  • Biochemical bases of the pharmacological action of the flavonoid silymarin and of its structural isomer silibinin
  • Bioactivity of neolignans from fructus Schizandrae
    Li XY [1991]
  • Bile acids : regulation of apoptosis by ursodeoxycholic acid
    Amaral JD [2009]
  • Bifidobacterium pseudocatenulatum CECT 7765 reduces obesity-associated inflammation by restoring the lymphocyte-macrophage balance and gut microbiota structure in high-fat diet-fed mice
  • Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis
  • Beneficial effect of branched-chain amino acid supplementation on glycemic control in chronic hepatitis C patients with insulin resistance : implications for type 2 diabetes
    Takeshita Y [2012]
  • BCAA-enriched snack improves nutritional state of cirrhosis
    Nakaya Y [2007]
  • Association of daily aspirin therapy with risk of hepatocellular carcinoma in patients with chronic hepatitis B
    Lee TY [2019]
  • Association of daily aspirin therapy with hepatocellular carcinoma risk in patients with chronic hepatitis c virus infection
    Lee TY [2020]
  • Association of aspirin with hepatocellular carcinoma and liver-related mortality
    Simon TG [2020]
  • Association of aspirin and statin use with the risk of liver cancer in chronic hepatitis B : a nationwide population-based study
    Choi WM [2021]
  • Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B
    Yun Bin Lee [2019]
  • Association between aspirin use and the prevalence of nonalcoholic fatty liver disease : a cross-sectional study from the third national health and nutrition examination survey
    Shen H [2014]
  • Association between aspirin use and risk of hepatocellular carcinoma
    Simon TG [2018]
  • Aspirin use is associated with lower indices of liver fibrosis among adults in the United States
    Jiang ZG [2016]
  • Aspirin use and the incidence of hepatocellular carcinoma in patients with hepatitis B virus or hepatitis C virus infection: a meta-analysis of cohort studies
    Li X [2021]
  • Aspirin targets P4HA2 through inhibiting NF-κB and LMCD1-AS1/let-7g to inhibit tumour growth and collagen deposition in hepatocellular carcinoma
    Wang T [2019]
  • Aspirin reduces the incidence of hepatocellular carcinoma in patients with chronic hepatitis b receiving oral nucleos(t)ide analog
    Hui VW [2021]
  • Aspirin is associated with low recurrent risk in hepatitis B virus-related hepatocellular carcinoma patients after curative resection
    Young SH [2020]
  • Aspirin in combination with TACE in treatment of unresectable HCC : a matched-pairs analysis
    Li JH [2016]
  • Aspirin decreases hepatocellular carcinoma risk in hepatitis C virus carriers : a nationwide cohort study
    Liao YH [2020]
  • Aspartateornithine granules in the treatment of nonalcoholic steatohepatitis : a multiple-dose parallel controlled clinical trial
    Tian LY [2013]
  • Antiplatelet therapy is associated with a better prognosis for patients with hepatitis B virus-related hepatocellular carcinoma after liver resection
    Lee PC [2016]
  • Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepatitis B patients on antiviral treatment
    Lee M [2017]
  • Antiplatelet drug therapy moderates immune-mediated liver disease and inhibits viral clearance in mice infected with a replication-deficient adenovirus
    Iannacone M [2007]
  • Antioxidant drugs combined with alpha-interferon in chronic hepatitis C not responsive to alpha-interferon alone : a randomized, multicentre study
    Idéo G [1999]
  • Antiapoptotic effect of DDB against hepatic ischemia-reperfusion injury
    El-Bahy AA [2011]
  • Anti-fibrotic effects of branched-chain amino acids on hepatic stellate cells
    Hae Lim Lee [2022]
  • An updated systematic review with meta-analysis for the clinical evidence of silymarin
    Saller R [2008]
  • An openlabel randomized control study to compare the efficacy of vitamin E versus ursodeoxycholic acid in nondiabetic and noncirrhotic Indian NAFLD patients
    Parikh P [2016]
  • Ammonia : a novel target for the treatment of non-alcoholic steatohepatitis
    Thomsen KL [2018]
  • Amino acids and leucine allow insulin activation of the PKB/mTOR pathway in normal adipocytes treated with wortmannin and in adipocytes from db/db mice
    Hinault C [2004]
  • Alterations in sulfur amino acid metabolism in mice treated with silymarin : a novel mechanism of its action involved in enhancement of the antioxidant defense in liver
    Kwon DY [2013]
  • Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis
    Abraldes JG [2016]
  • A systematic review of the safety of probiotics
    Didari T [2014]
  • A randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis
  • A randomized pilot trial of oral branchedchain amino acids in early cirrhosis : validation using prognostic markers for pre-liver transplant status
    Kawamura E [2009]
  • A randomized controlled, double-blind evaluation of the short-term(8weeks)efficacy and safety of godex in Korean chronic hepatitis patients
    Kang JS [2001]
  • A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis
    Ratziu V [2011]
  • A randomized controlled trial of branched-chain amino acid(BCAA)-enriched elemental diet(ED-H)for hepatic encephalopathy
    Hayashi S [1991]
  • A randomized controlled trial comparing the effects of vitamin E, ursodeoxycholic acid and pentoxifylline on Egyptian non-alcoholic steatohepatitis patients
    Fouda A [2021]
  • A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis
    Mitchell SA [2001]
  • A placebo-controlled trial of silymarin in patients with nonalcoholic fatty liver disease
    Hashemi SJ [2009]
  • A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis : a randomized placebo-controlled trial
    Nelson A [2009]
  • A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis
    Sanyal AJ [2004]
  • A multi-strain probiotic reduces the fatty liver index, cytokines and aminotransferase levels in NAFLD patients : evidence from a randomized clinical trial
    Kobyliak N [2018]
  • A morphological method for ammonia detection in liver
  • A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C
    Omata M [2007]
  • A century of cholesterol and coronaries : from plaques to genes to statins
  • 8-Hydroxy-2’-deoxy-guanosine is a risk factor for development of hepatocellular carcinoma in patients with chronic hepatitis C virus infection
    Chuma M [2008]